Keyphrases
Maximum Tolerated Dose
100%
Dose-limiting Toxicity
100%
Lymphoma
100%
Phase I Study
100%
Orally Administered
100%
Idarubicin
100%
Plasma Concentration
28%
Antitumor Efficacy
28%
Dose Escalation
14%
Lymph Node
14%
Owned Dogs
14%
Hematologic
14%
Antitumor Activity
14%
Repeated Dose
14%
Anthracyclines
14%
Thrombocytopenia
14%
Randomized Clinical Trial
14%
Clinical Benefit
14%
Neutropenia
14%
Clinical Significance
14%
Single Oral Dose
14%
Bioavailable
14%
Pharmacokinetic Parameters
14%
Cohort Design
14%
Skin Lesions
14%
Anthracycline Antibiotics
14%
Modified RECIST
14%
Antibiotic Class
14%
Alternative Supports
14%
Similarity Classes
14%
Number of Patients
14%
Dose Level
14%
Pharmacology, Toxicology and Pharmaceutical Science
Idarubicin
100%
Maximum Tolerated Dose
100%
Idarubicinol
28%
Antitumor Activity
14%
Randomized Clinical Trial
14%
Pharmacokinetic Parameter
14%
Skin Defect
14%
Anthracycline Antibiotic Agent
14%
Thrombocytopenia
14%
Neutropenia
14%
Anthracycline
14%